Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Altria Group Inc (MO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Altria Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.47 (market cap $39.89B), while Altria Group Inc trades at $71.8 (market cap $119.88B). The key difference: Altria Group Inc is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and Altria Group Inc pays a 5.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MO | |
|---|---|---|
Market Cap | $39.89B | $119.88B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $74.55 |
52-Week Low | $278.09 | $54.72 |
Enterprise Value | $38.15B | $140.95B |
Dividend Yield | — | 5.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Altria Group (MO) trades at $71.77, up 0.25% on the day, with a bullish technical signal and strong analyst support (16 buy ratings). The stock exhibits robust fundamentals, including a P/E of 14.99, net income margin of 39.52%, and consistent dividend payments, highlighted by a recent $1.06 dividend. Revenue remains stable around $20.1B, though net income dipped to $6.95B in 2025 from $11.3B in 2024. Positive cash flow of $1.33B in 2025 supports financial health, while technical indicators show support at $71 and resistance at $73.
Outlook: MO offers a compelling dividend yield and defensive appeal amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus price target is $71.00, with potential upside to $79.00. Investors should weigh high debt levels and competitive threats against strong cash flow and brand loyalty for long-term income stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
